The targeting of the BCR-ABL fusion protein for Chronic Myeloid Leukemia (CML) was a departure from previous cancer chemotherapies because:
a. It targeted a protein unique to a specific cancer, rather than fundamental universal cellular process.
b. It was the first drug to be approved from a High-Throughput Screening campaign.
c. It was the first drug to be approved that originated in a rational drug design effort (using crystal structures to guide design).
d. It has the fastest approval time from initial target ID to treatment of patients of any drug to date.